Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis

被引:69
作者
Hamza, Omar J. M. [1 ]
Matee, Mecky I. N. [2 ]
Moshi, Mainen J. [3 ]
Simon, Elison N. M. [1 ]
Mugusi, Ferdinand [4 ]
Mikx, Frans H. M. [5 ]
Helderman, Wim H. van Palenstein [5 ]
Rijs, Antonius J. M. M. [6 ,7 ]
van der Ven, Andre J. A. M. [7 ,8 ]
Verweij, Paul E. [6 ,7 ]
机构
[1] Muhimbili Univ Hlth & Allied Sci, Dept Oral Surg & Oral Pathol, Dar Es Salaam, Tanzania
[2] Muhimbili Univ Hlth & Allied Sci, Dept Microbiol & Immunol, Dar Es Salaam, Tanzania
[3] Muhimbili Univ Hlth & Allied Sci, Inst Tradit Med, Dept Biol & Preclin Studies, Dar Es Salaam, Tanzania
[4] Muhimbili Univ Hlth & Allied Sci, Dept Internal Med, Dar Es Salaam, Tanzania
[5] Radboud Univ Nijmegen, Med Ctr, WHO Collaborating Ctr, NL-6525 ED Nijmegen, Netherlands
[6] Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, NL-6525 ED Nijmegen, Netherlands
[7] Univ Nijmegen, Ctr Infect Dis, Nijmegen, Netherlands
[8] Radboud Univ Nijmegen, Med Ctr, Dept Gen Internal Med, NL-6525 ED Nijmegen, Netherlands
关键词
D O I
10.1186/1471-2180-8-135
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: In Tanzania, little is known on the species distribution and antifungal susceptibility profiles of yeast isolates from HIV-infected patients with primary and recurrent oropharyngeal candidiasis. Methods: A total of 296 clinical oral yeasts were isolated from 292 HIV-infected patients with oropharyngeal candidiasis at the Muhimbili National Hospital, Dar es Salaam, Tanzania. Identification of the yeasts was performed using standard phenotypic methods. Antifungal susceptibility to fluconazole, itraconazole, miconazole, clotrimazole, amphotericin B and nystatin was assessed using a broth microdilution format according to the guidelines of the Clinical and Laboratory Standard Institute ( CLSI; M27-A2). Results: Candida albicans was the most frequently isolated species from 250 ( 84.5%) patients followed by C. glabrata from 20 ( 6.8%) patients, and C. krusei from 10 ( 3.4%) patients. There was no observed significant difference in species distribution between patients with primary and recurrent oropharyngeal candidiasis, but isolates cultured from patients previously treated were significantly less susceptible to the azole compounds compared to those cultured from antifungal nave patients. Conclusion: C. albicans was the most frequently isolated species from patients with oropharyngeal candidiasis. Oral yeast isolates from Tanzania had high level susceptibility to the antifungal agents tested. Recurrent oropharyngeal candidiasis and previous antifungal therapy significantly correlated with reduced susceptibility to azoles antifungal agents.
引用
收藏
页数:9
相关论文
共 44 条
[1]  
[Anonymous], 1980, COMMUNITY DENT ORAL, V8, P1
[2]   IN-VITRO ACTIVITY OF ITRACONAZOLE AGAINST FLUCONAZOLE-SUSCEPTIBLE AND FLUCONAZOLE-RESISTANT CANDIDA-ALBICANS ISOLATES FROM ORAL CAVITIES OF PATIENTS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS [J].
BARCHIESI, F ;
COLOMBO, AL ;
MCGOUGH, DA ;
FOTHERGILL, AW ;
RINALDI, MG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (07) :1530-1533
[3]   Fluconazole susceptibility and strain variation of Candida albicans isolates from HIV-infected patients with oropharyngeal candidosis [J].
Barchiesi, F ;
Arzeni, D ;
Del Prete, MS ;
Sinicco, A ;
Di Francesco, LF ;
Pasticci, MB ;
Lamura, L ;
Nuzzo, MM ;
Burzacchini, F ;
Coppola, S ;
Chiodo, F ;
Scalise, G .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (05) :541-548
[4]   Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy [J].
Barchiesi, F ;
Maracci, M ;
Radi, B ;
Arzeni, D ;
Baldassarri, I ;
Giacometti, A ;
Scalise, G .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (06) :999-1002
[5]  
Blignaut E, 1999, SADJ, V54, P605
[6]   Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals [J].
Blignaut, E ;
Messer, S ;
Hollis, RJ ;
Pfaller, MA .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 44 (02) :169-174
[7]   Oral candidiasis and oral yeast carriage among institutionalised South African paediatric HIV/AIDS patients [J].
Blignaut, Elaine .
MYCOPATHOLOGIA, 2007, 163 (02) :67-73
[8]   Oral candidiasis as a clinical marker related to viral load, CD4 lymphocyte count and CD4 lymphocyte percentage in HIV-infected patients [J].
Campo, J ;
Del Romero, J ;
Castilla, J ;
García, S ;
Rodríguez, C ;
Bascones, A .
JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2002, 31 (01) :5-10
[9]   Non-albicans oral candidosis in HIV-positive patients [J].
Cartledge, JD ;
Midgley, J ;
Gazzard, BG .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (03) :419-422
[10]   CROSS-SECTIONAL STUDY OF THE SUSCEPTIBILITY OF CANDIDA ISOLATES TO ANTIFUNGAL DRUGS AND IN-VITRO IN-VIVO CORRELATION IN HIV-INFECTED PATIENTS [J].
CHAVANET, P ;
LOPEZ, J ;
GRAPPIN, M ;
BONNIN, A ;
DUONG, M ;
WALDNER, A ;
BUISSON, M ;
CAMERLYNCK, P ;
PORTIER, H .
AIDS, 1994, 8 (07) :945-950